

# Enhertu

## (fam-trastuzumab deruxtecan-nxki)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Enhertu (fam-trastuzumab deruxtecan-nxki)

### **APPROVAL CRITERIA**

Requests for Enhertu (fam-trastuzumab deruxtecan-nxki) may be approved if the following criteria are met:

- I. Individual has a diagnosis of unresectable or metastatic HER2-positive (HER2+) breast cancer (Label, NCCN 1) confirmed by *one* of the following:
  - A. Immunohistochemistry (IHC) is 3 +; **OR**
  - B. In situ hybridization (ISH) positive;

#### **AND**

- II. Individual has previously received a prior anti-HER2 therapy in either:
  - A. Metastatic setting; **OR**
  - B. In the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy;

#### **OR**

- III. Individual has a diagnosis of unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (Label, NCCN 1)); **AND**
- IV. Individual is using as single-agent therapy;

#### **OR**

- V. Individual has a diagnosis of unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations and who have received a prior systemic therapy (Label, NCCN 2A));

#### **OR**

- VI. Individual has a diagnosis of HER2+ gastric or gastroesophageal junction adenocarcinoma confirmed by *one* of the following (Label, NCCN 2A):
  - A. Immunohistochemistry (IHC) is 3 +;**OR**

B. In situ hybridization (ISH) positive;

**AND**

VII. Individual has had received a prior trastuzumab (or trastuzumab biosimilars)-based regimen;

**OR**

VIII. Individual has a diagnosis of metastatic HER2 + breast cancer with brain metastases and the following criteria are met (NCCN 2A):

A. Individual has a primary diagnosis of HER2+ breast cancer; **AND**

B. Using in one of the following ways:

1. In those with asymptomatic brain metastases as primary or initial therapy; **OR**

2. In those with stable brain metastases disease in relapsed/recurrent disease;

**AND**

C. Individual is using as a single-agent treatment.

Requests for Enhertu (fam-trastuzumab deruxtecan-nxki) may not be approved for the following:

I. When Enhertu is used in combination with other targeted biologic agents or chemotherapy agents; **OR**

II. When the above criteria are not met and for all other indications.

**NOTE:**

Enhertu has a black box warning for interstitial lung disease and embryo-fetal toxicity. Interstitial lung disease (ILD) and pneumonitis, including fatal cases, have been reported with Enhertu. Patients should be monitored for signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Enhertu should be discontinued in all patients with Grade 2 or higher ILD/pneumonitis.

**Key References:**

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2023. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. Cortés J, Kim S-B, Chung W-P, et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with HER2+ metastatic breast cancer: results of the randomized, phase 3 study DESTINY-Breast03. ESMO 2021
3. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: January 17, 2023.
4. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
5. Jerusalem G, Park YH, Yamashita T, et al. Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: a subgroup analysis of the DESTINY-Breast01 trial. ASCO 2021
6. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2023; Updated periodically.
7. Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive breast Cancer. N Eng J Med 2019; 10.1056/NEJMoa1914510.
8. NCCN Clinical Practice Guidelines in Oncology™. © 2023 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on January 17, 2023.

- a. Breast Cancer. V4.2022. Revised June 21, 2022.
- b. Central Nervous System Cancers. V2.2022. Revised September 29, 2022.
- c. Colon Cancer. V2.2022. Revised October 27, 2022.
- d. Esophageal and esophagogastric junction cancers. V5.2022. Revised December 5, 2022.
- e. Gastric Cancer. V2.2022. Revised January 11, 2022.
- f. Head and neck Cancers. V1.2023. Revised December 20, 2022.
- g. Non-Small Cell Lung Cancer. V1.2023. Revised December 22, 2022.
- h. Rectal Cancer. V3.2022. Revised October 27, 2022.
9. Siena S, Di Bartolomeo M, Raghav KPS, et. al. A phase II multicenter, open-label study of trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer: DESTINY-CRC01. J Clin Oncol 2020; 38 (suppl;abstr 4000).
10. Smit EF, Nakagawa K, Nagasaka M, et.al. Trastuzumab deruxtecan in patients with HER2-mutated metastatic non-small cell lung cancer; interim results of DESTINY-Lung01[abstract]. J Clin Oncol 2020;38;Abstract 9504.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.